Live news related to OXURION stock (BE0974487192): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on OXURION mainly cover analyst notes et M&A activity. The stock trades at €0,00 on Euronext Paris, up 8,33% at the last update. This page lists the articles published on OXURION stock to track the share price, company announcements and any item likely to influence market perception.
Oxurion has announced that its subsidiary Axiodis CRO has entered into a strategic partnership with KYomed INNOV & CEISO, a French CRO specializing in…
Oxurion has announced the commercial launch of the electronic Trial Master File (eTMF) module of its Exagis platform, developed by its subsidiary Axio…
Oxurion announced on Monday that Pierre Fabre Laboratories is utilizing Exagis, its proprietary clinical data management platform developed by its sub…
The Belgian biopharmaceutical group Oxurion announced on Monday the launch of a growth strategy centered on Exagis, its clinical data management softw…
The Belgian biopharmaceutical group Oxurion announced on Tuesday the launch of a dedicated service offering for GLP-1-based therapies, peptides, and b…
Belgian biotech company Oxurion has ended discussions on acquiring a French Contract Research Organization (CRO), previously announced in October 2025…
Oxurion received a transparency notification on Thursday indicating that Atlas Special Opportunities II LLC has reduced its stake below the 15% thresh…
Oxurion has signed a letter of intent to acquire 75% of a contract research organization (CRO) operating in Europe, North Africa, and the Middle East.…
Biopharmaceutical company Oxurion has signed a fourth amendment to its financing agreement with Atlas Special Opportunities II, LLC, extending its con…
Axiodis CRO, a subsidiary of the Oxurion group, announces an acceleration of its commercial and marketing strategy. This initiative includes the recru…
